David Sinclair to co-chair $200 million biotech SPAC

Author: Danny Sullivan | Published on: March 11, 2021 | Last updated: January 23, 2023

Christian Angermayer’s Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board.

Frontier Acquisition Corporation, a special purpose acquisition company formed for the purpose of entering into a combination with one or more biotech businesses, has announced the pricing of its initial public offering of $200 million. Interestingly, the line-up includes Co-Chairmen Peter Attia, a practising physician focusing on the applied science of longevity and co-founder and chief medical officer of the fasting app Zero, and David Sinclair, Professor of Genetics at Harvard Medical School and co-founder of several biotechnology companies.

co-founder and Chief Medical Officer of the fasting app Zero. — Peter Attia, Co-Chairman and Co-founder and Chief Medical Officer of Zero.

The new company is headed by German investor Christian Angermayer, founder of Apeiron Investment Group and Chairman & Co-Founder of Cambrian Biopharma. Angermayer laid out his views last year in a detailed post on LinkedIn, where he stated, “Put simply, I want to live forever! And in perfect health! And it is my sincere belief that we will achieve the means to do this within the next 20-30 years.”

Longevity.Technology: Another major biotech SPAC would already be exciting news for the longevity sector, but it becomes even more thrilling when you add people like David Sinclair and Peter Attia in to the mix. We’re watching with great interest!

In a press release the company said, that it “intends to pursue opportunities at the intersection of the healthcare and technology industries,” but that it “will not be limited to a particular industry or geographic region in its identification and acquisition of a target company.”

Angermayer is a serial entrepreneur, backing about 30 life sciences companies, including Atai Life Sciences, Sensei Biotherapeutics, Compass Pathways and Abcellera. In a statement on LinkedIn, he said, “I deeply believe biotechnology will be one of the best asset classes to invest in over the next decade. We will see incredible progress that we so far didn’t dare to dream about.

“We at Apeiron Investment Group want to back the best entrepreneurs with the boldest ideas and help make their vision a reality. When it comes to financing, there is never a “one-size-fits-all”. We can offer the entire spectrum of financing options, from early stage support and company creation, to venture growth financing to IPO support and, as of today, financing via SPAC merger.

“I am very proud to partner with legends David Sinclair and Peter Attia, as well as Falcon Edge Capital!”

Frontier Acquisition is sponsored by an affiliate of Falcon Edge Capital and Apeiron Investment Group, and the IPO is based on pricing of 20,000,000 units at a price of $10.00 per unit. Beginning today, the units will be listed on the Nasdaq Capital Market and trade under the ticker symbol “FRONU”. Once the securities comprising the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed on the Nasdaq Capital Market under the symbols “FRON” and “FRONW,” respectively.